Biocartis NVPRESS RELEASE - 06/05/2024, 07:00 CESTBiocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) RegionBiocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and North Africa (MEA) region. The Idylla™ KRAS Mutation Test and Idylla™ NRAS-BRAF Mutation Test are highly performant6 Tests that rapidly determine the RAS biomarker status in mCRC tumor tissue samples. Due to the ease-of-use of the Biocartis Idylla™ Platform, the Tests can be deployed in any user setting and in turn aid patient access to biomarker testing globally. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis.
